S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Drought-struck Barcelona quenches thirst with costly desalination
NASDAQ:GTHX

G1 Therapeutics (GTHX) Stock Forecast, Price & News

$2.62
-0.07 (-2.60%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$2.61
$2.68
50-Day Range
$2.46
$3.15
52-Week Range
$2.38
$17.49
Volume
543,100 shs
Average Volume
1.12 million shs
Market Capitalization
$135.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.60

G1 Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
533.6% Upside
$16.60 Price Target
Short Interest
Healthy
6.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
1.48mentions of G1 Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.44) to ($1.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

309th out of 1,010 stocks

Pharmaceutical Preparations Industry

131st out of 494 stocks


GTHX stock logo

About G1 Therapeutics (NASDAQ:GTHX) Stock

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GTHX Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
BTIG Sticks to Its Buy Rating for G1 Therapeutics (GTHX)
H.C. Wainwright Keeps Their Buy Rating on G1 Therapeutics (GTHX)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Recap: G1 Therapeutics Q1 Earnings
Earnings Preview: G1 Therapeutics
What 6 Analyst Ratings Have To Say About G1 Therapeutics
See More Headlines
Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GTHX Company Calendar

Last Earnings
5/03/2023
Today
5/29/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GTHX
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.60
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+533.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-147,560,000.00
Net Margins
-219.66%
Pretax Margin
-216.69%

Debt

Sales & Book Value

Annual Sales
$57.35 million
Book Value
$1.60 per share

Miscellaneous

Free Float
47,409,000
Market Cap
$135.35 million
Optionable
Optionable
Beta
1.93

Key Executives

  • Jack Bailey
    President, Chief Executive Officer & Director
  • Terry L. Murdock
    Chief Operating Officer
  • John Umstead
    Chief Financial Officer
  • Rajesh K. MalikRajesh K. Malik
    Chief Medical Officer
  • Mark Avagliano
    Chief Business Officer













GTHX Stock - Frequently Asked Questions

Should I buy or sell G1 Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GTHX shares.
View GTHX analyst ratings
or view top-rated stocks.

What is G1 Therapeutics' stock price forecast for 2023?

6 equities research analysts have issued twelve-month price targets for G1 Therapeutics' shares. Their GTHX share price forecasts range from $10.00 to $25.00. On average, they predict the company's share price to reach $16.60 in the next year. This suggests a possible upside of 533.6% from the stock's current price.
View analysts price targets for GTHX
or view top-rated stocks among Wall Street analysts.

How have GTHX shares performed in 2023?

G1 Therapeutics' stock was trading at $5.43 at the beginning of 2023. Since then, GTHX stock has decreased by 51.7% and is now trading at $2.62.
View the best growth stocks for 2023 here
.

Are investors shorting G1 Therapeutics?

G1 Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 3,120,000 shares, a decrease of 5.7% from the April 30th total of 3,310,000 shares. Based on an average daily volume of 938,200 shares, the days-to-cover ratio is currently 3.3 days.
View G1 Therapeutics' Short Interest
.

When is G1 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our GTHX earnings forecast
.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) issued its earnings results on Wednesday, May, 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.11. The business had revenue of $12.95 million for the quarter, compared to analysts' expectations of $10.54 million. G1 Therapeutics had a negative net margin of 219.66% and a negative trailing twelve-month return on equity of 222.92%.

What ETFs hold G1 Therapeutics' stock?

ETFs with the largest weight of G1 Therapeutics (NASDAQ:GTHX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (5.27%), JPMorgan Chase & Co. (4.16%), BlackRock Inc. (2.68%), FMR LLC (1.87%), Raymond James & Associates (1.45%) and Bank of America Corp DE (1.17%). Insiders that own company stock include Andrew Perry, Glenn P Muir, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock.
View institutional ownership trends
.

How do I buy shares of G1 Therapeutics?

Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $2.62.

How much money does G1 Therapeutics make?

G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $135.35 million and generates $57.35 million in revenue each year. The company earns $-147,560,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis.

How many employees does G1 Therapeutics have?

The company employs 148 workers across the globe.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for the company is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830.

This page (NASDAQ:GTHX) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -